What is PredictImmune?
Founded in 2017 and headquartered in Cambridge, England, PredictImmune is at the forefront of developing prognostic tests designed to identify and manage immune-mediated diseases. The company's focus on leveraging immunological insights aims to provide critical diagnostic tools for clinicians, potentially improving patient outcomes and treatment strategies in a complex and often challenging area of medicine. Their work positions them as a key player in the health technology sector, specifically within the diagnostics and precision medicine landscape.
How much funding has PredictImmune raised?
PredictImmune has raised a total of $16.6M across 2 funding rounds:
Series A
$5.9M
Series B
$10.7M
Series A (2018): $5.9M with participation from The Wellcome Trust
Series B (2019): $10.7M led by Parkwalk and BFG
Key Investors in PredictImmune
The Wellcome Trust
Wellcome is an independent global charitable foundation based in London that supports discovery research and tackles urgent health challenges, funding science, policy and public engagement to improve health for people everywhere through grants, partnerships and advocacy.
Parkwalk
Parkwalk is a leading investor in university spinouts, focusing on deeptech innovations emerging from the UK's top universities. With over 15 years of experience, they bridge the gap between academic research and commercial success by providing funding, expertise, and networks to help these companies thrive.
BFG
Undisclosed investor participating in the funding round.
What's next for PredictImmune?
With substantial enterprise-level funding and a recent strategic investment, PredictImmune is poised for significant growth and expansion. The capital infusion is expected to fuel further research and development, enhance their commercialization efforts, and potentially broaden the application of their prognostic tests across a wider range of immune-mediated conditions. This strategic backing suggests a strong market validation and confidence in PredictImmune's technology and its potential to disrupt the diagnostics market, paving the way for future scaling and market penetration.
See full PredictImmune company page
